CASE 2 48 yo man IVDU in past….last used 27 yrs ago Stable social situation Currently receiving social assistance with provincial drug coverage No comorbid.

Slides:

Advertisements

Similar presentations

Optimal therapy in genotype 2 and 3 patients Antonio Craxì Liver & GI Unit, Di.Bi.M.I.S., University of Palermo, Italy

Advertisements

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

TWH LIVER CENTRE UHN centre of excellence A case study: Hepatitis C treatment and severe anemia Colina Yim RN(EC), MN Nurse Practitioner CAHN 2013.

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

Management of non naïve patients with hepatitis C Relapsers Alessandra Mangia Liver Unit & Division of Gastroenterology “CSS” San Giovanni Rotondo, Italy.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin + Peginterferon in Genotypes 1-3 PROTON Phase 2 Treatment Naïve Lawitz E, et al. Lancet.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Experienced GT-1 REALIZE (Study 216) Phase 3 Treatment Experienced Zeuzem S, et al. N Engl.

Hepatitis web study Hepatitis web study Sofosbuvir, Ribavirin, GS-0938 in GT 1-4 QUANTUM Phase 2b Treatment Naïve Lalezari JP, et al. EASL. 2013; Abstract.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ADVANCE (Study 108) Phase 3 Treatment Naïve Jacobson IM, et. al. N Engl J Med.

Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.

Hepatitis web study Hepatitis web study Simeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial Phase 3 Treatment Naïve Jacobson IM, et al.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3 Phase 3 Treatment Naïve, Chronic HCV Mangia A, et.

Hepatitis web study Hepatitis web study 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I Phase 3 Treatment Naïve Feld JJ, et.

Hepatitis web study Hepatitis web study Simeprevir in HIV Coinfection, GT-1 C212 Trial Phase 3 Treatment Naïve and Treatment Experienced Dieterich D, et.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

Why GIVE a Liver Transplant to Patients with GAVE Syndrome

Hepatitis web study Hepatitis web study Interferon alfa-2b +/- Ribavirin for 24 or 48 weeks Phase 3 Treatment Naïve, Chronic HCV McHutchison JG, et al.

Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:

Long-Term Efficacy of Dapagliflozin in T2DM Patients Receiving High-Dose Insulin John P.H. Wilding, DM, FRCP 

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.

Hepatitis web study Hepatitis web study Sofosbuvir ELECTRON (Overview): 6 parts, 22 arms Phase 2 Treatment Naïve and Treatment Experienced Source: Gilead.

Response Guided Therapy Fabien Zoulim Hepatology Department & INSERM Unit 1052, Lyon University Lyon, France.

Maria Buti Hospital General Universitario Vall Hebron Barcelona-. Spain Relapser or Non Responder? Chronic Hepatitis C.

Hepatitis web study Hepatitis web study Simeprevir with Peginterferon and Ribavirin in GT-4 RESTORE Phase 3 Treatment Naïve and Treatment Experienced Moreno.

Randomisation* 2 : 1 Double blind *Randomisation was stratified on genotype (1a or 1b or other) and IL28B genotype (CC, CT or TT) N = 133 N = 260 W24W48.

How to manage G1 relapsers and non-responders George V. Papatheodoridis, MD Associate Professor in Medicine & Gastroenterology 2nd Department of Internal.

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs CD4 310/40% HIV Viral Load

5 th Paris Hepatitis Congress Workshop 30/1/2012 Managing complications of DAAs: Case 1 Dr Samuel S. Lee University of Calgary.

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.

CASE 3 62 yo man Genotype 1b chronic hepatitis C Cirrhosis No previous ascites/encephalopathy OGD revealed a few very small esophageal varices.

SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.

Hepatitis web study Hepatitis web study Sofosbuvir + RBV in Treatment-Naïve Genotypes 2,3 FISSION Trial* Phase 3 *Note: Published in NEJM in tandem with.

SOF/VEL 400/100 mg qd N = 75 W24 SOF/VEL > 18 years Chronic HCV infection Genotype 1 to 6 Naïve or treatment-experienced No prior treatment with NS5A or.

SMV + DCV + SOF Open label Chronic HCV infection Genotype 1 or 4 Treatment-naïve or pre-treated with PEG-IFN ± RBV Portal hypertension or liver decompensation.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 AI Trial Phase 2a Treatment-Naïve and Treatment-Experienced.

Hepatitis web study Hepatitis web study Boceprevir with PEG + RBV in Genotype 1 SPRINT-1 Phase 2 Treatment Naïve Kwo PY, et al. Lancet. 2010;376:

CASE 2 58 yo man IVDU in past….last used 35 yrs ago Genotype 1a Chronic Hepatitis C Type II Diabetes Private drug plan coverage.

CASE 3 48 yo man HIV positive/HEP C positive 12 yrs. ago Tenofovir/FTC/RTV/Lopinavir x 7 yrs. CD4 310/40% HIV Viral Load

Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.

Hepatitis web study Hepatitis web study Simeprevir versus Telaprevir with PR in GT1 ATTAIN Trial Phase 3 Treatment Experienced Reddy KR, et al. Lancet.

CASE 1 54 yo man HIV positive 8 yrs ago Tenofovir/FTC/RTV/Atazanavir x 4 yrs Previously documented NNRTI resistance with Y181C, G190A,and mixed m184v/wt.

 Design Open-label years Chronic HCV infection Genotype 1 HCV RNA > 10,000 IU/mL HIV co-infection Stable ART* with HIV RNA < 50 c/mL ≥ 24 weeks.

Short-term effects of combination of satavaptan, a selective vasopressin V 2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without.

LDV/SOF Randomisation * 1:1 Open-label ≥ 20 years, Japanese Chronic HCV infection Genotype 1 HCV RNA ≥ IU/ml Treatment-naive, or pre-treated Compensated.

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

C-ISLE study: EBR/GZR + SOF + RBV in genotype 3 and cirrhosis

Complicated cases David Fletcher, MD Department of Medicine University of Toronto.

Phase 2 Treatment Naïve HIV Coinfection

Boceprevir in Treatment Naive SPRINT-2

Simeprevir in HIV Coinfection, GT-1 C212 Trial

(Treatment Failure Trial)

Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I

HCV Protease Inhibitors in Clinical Practice

ARV-trial.com IMPACT Study: SMV + DCV + SOF in HCV genotype 1 with decompensated liver disease Design Open label ≥ 18 years Chronic HCV infection Genotype.

GS-US Study: SOF/VEL + GS-9857 in genotype 1 - Phase II

Phase 3 Treatment-Naïve and Treatment-Experienced

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2

Phase 2 Treatment Naïve and Treatment Experienced

ARV-trial.com TURQUOISE-I Study: ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin for HCV in HIV co-infected patients Randomisation 1 : 1 Open-label.

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

HCV Protease Inhibitors in Clinical Practice

CONCERTO-4 Study: SMV + PEG-IFNa-2b + RBV for genotype 1

Sequencing cohorts Open-label Design W8 W12 ≥ 18 years

Presentation transcript:

CASE 2 48 yo man IVDU in past….last used 27 yrs ago Stable social situation Currently receiving social assistance with provincial drug coverage No comorbid disease

CASE 2 Hepatitis C disease parameters Secondary workup negative…no co- infections HCVRNA 3.65 x 10E7 iu/ml genotype 1a

CASE 2 Hepatitis C disease parameters AST>ALT Platelets 71 INR 1.5 Bilirubin 38 mmol/l

CASE 2 Hepatitis C disease parameters Clinically…no previous ascites/edema, encephalopathy or GI bleeds Imaging…coarse liver/14cm spleen/no free fluid/no varices seen OGD…no varices

CASE 2 Under what circumstances would you not treat a cirrhotic patient for Hepatitis C? Ascites…previous vs current Encephalopathy Portal Hypertension without previous bleed/with previous bleed Are there biochemical exclusionary criteria for treatment

CASE 2 Treatment initiated with Peg INF/1400mg RBV (90kg) Week 0 HCVRNA…3.65x 10E7 Week 4 HCVRNA…1.12x10E2 Severe nausea/intolerable…RBV decreased to 1200mg/day

CASE 2 Peg INF/1200mg RBV (90kg) Week 4-8 Increasing abdominal girth/soas responsive to a slow diuresis with furosemide and salt restriction No encephalopathy SBP prophylaxis initiated

CASE 2 Peg INF/1200mg RBV (90kg) Week 4-8 Increase in bilirubin from 40 to 75 then stabilized Inr increased from 1.5 to 1.7 then stabilized Plts decreased from 80 to 40 then stabilized Renal function stable throughout with creatinine at 55 mmole/l

CASE 2 Peg INF/1200mg RBV (90kg) Week 0 HCVRNA…3.65x 10E7 Week 4 HCVRNA…1.12x10E2 Week 8 HCVRNA…8.80x10E1

CASE 2 Peg INF/1200mg RBV (90kg) Week 8 Stable clinically with 1.5 kg of weight loss weekly and tolerating therapy day-day relatively well Warned of concerns re: stalling of HCVRNA but decision to continue therapy made

CASE 2 Peg INF/1200mg RBV (90kg) Week 0 HCVRNA…3.65x 10E7 Week 4 HCVRNA…1.12x10E2 Week 8 HCVRNA…8.80x10E1 Week 12 HCVRNA…5.40 x 10E1 WHAT WOULD YOU DO TODAY?

CASE 2 Peg INF/1200mg RBV (90kg) Week 12 Boceprevir access arranged and therapy initiated at 800mg Q8H

CASE 2 Peg INF/1200mg RBV/Boceprevir 800mg Q8H (90kg) Week Adherent with all meds and Boceprevir addition tolerated well Erythropoietin initiated at week 15

CASE 2 Peg INF/1200mg RBV/Boceprevir 800 mg Q8H (90kg) Week 0 HCVRNA…3.65x 10E7 Week 4 HCVRNA…1.12x10E2 Week 8 HCVRNA…8.80x10E1 Week 12 HCVRNA x10E1 Week 16 (week 8)….undetectable

CASE 2 Questions: Do you think the dose reduction of RBV by 200mg stalled the progress of therapy? How long will you treat…is response guided therapy appropriate for this naïve patient? If week 16 (week 8 of triple therapy) was still detectable would you have continued with therapy?